More Americans Taking Home $100,000-Plus in Prescriptions

This version of More Americans Join Club Top Drug Spenders N358071 - Health and Medicine | NBC News Clone was adapted by NBC News Clone to help readers digest key facts more efficiently.

More Americans have joined the $100,000-plus spending club for prescriptions, a new report finds.
Get more newsMore Americans Join Club Top Drug Spenders N358071 - Health and Medicine | NBC News Cloneon

Pricey cancer drugs, expensive new cures for hepatitis and made-to-order drugs have driven U.S. prescription costs to new highs for some Americans, according to a report issued Wednesday.

It finds that more than half a million Americans each took home $50,000 or more worth of prescription drugs last year.

And the number of super-high spenders prescribed $100,000 or more worth of medications nearly tripled from 47,000 to 139,000, pharmacy benefits manager Express Scripts says.

These are often very sick people, the report found. “Among patients whose drug costs reached at least $100,000, more than one-third were treated for at least 10 conditions and more than 60 percent were taking at least 10 different prescription medications,” the report reads.

“Among patients whose drug costs reached at least $100,000, more than one-third were treated for at least 10 conditions."

For those spending $100,000 or more a year, specialty, made-to-order drugs known as compounded therapies, as well as drugs for hepatitis C and to treat cancer accounted for two-thirds of the costs, Express Scripts found.

The hepatitis C drugs include Gilead Science’s Sovaldi, which can cure the liver-destroying virus. Gilead charges $84,000 for the three-month drug course, and argues that it costs less than treating patients for a lifetime of liver disease.

Express Scripts, which has actively fought drug companies over their pricing, has refused to cover Gilead’s other expensive hepatitis C drug Harvoni, and instead negotiated a deal with rival drugmaker Abbvie to get its hepatitis C drug Viekira at a discount.

The benefits manager, which covers about 85 million Americans, has also complained about pricey cancer drugs. Bristol-Myers Squibb’s melanoma drug Yervoy can keep patients with terminal melanoma alive for a year or longer but it costs $120,000 for a course of treatment.

Patients are almost never bearing these high costs. Insurance plans covered more than 98 percent of the costs for patients whose drugs cost $100,000 or more in 2014. “Across the cost spectrum, patients in 2014 paid an average of 13.5 percent of their total medication costs, down from 14.9 percent in 2013,” the report reads.

"Patients are overwhelmingly taking specialty medications, and have multiple comorbidities, prescriptions and prescribers."

Express Scripts used data from 31.5 million insured Americans covered by commercial insurers, Medicare and Medicaid for its report.

“The profile emerging from this research shows these patients are overwhelmingly taking specialty medications, and have multiple comorbidities, prescriptions and prescribers,” said Dr. Glen Stettin, senior vice president for clinical research at Express Scripts.

The report found that 90 percent of patients with drug costs of $50,000 used specialty medications, which are expensive treatments for complex conditions. More than a third of them were being treated for 10 or more different medical conditions.

AdBlock Detected!
Please disable it to support our content.
×

Related Articles

Donald Trump Presidency Updates - Politics and Government | NBC News Clone | Joe Biden Campaign News - Politics and Government | NBC News Clone | Kamala Harris Vp Announcement - Politics and Government | NBC News Clone | Trump Indictment Latest - Politics and Government | NBC News Clone | Election Results Live - Politics and Government | NBC News Clone | Swing States Polling - Politics and Government | NBC News Clone | Debate Highlights - Politics and Government | NBC News Clone | Budget Approval 2025 - Politics and Government | NBC News Clone | Abortion Ruling - Politics and Government | NBC News Clone | Us China Relations - Politics and Government | NBC News Clone | Inflation Rates 2025 Analysis - Business and Economy | NBC News Clone | Federal Reserve Interest Rates - Business and Economy | NBC News Clone | Stock Market Today - Business and Economy | NBC News Clone | Recession Prediction 2025 - Business and Economy | NBC News Clone | Jobs Report Unemployment - Business and Economy | NBC News Clone | Ai Stock Surge - Business and Economy | NBC News Clone | Housing Market Crash - Business and Economy | NBC News Clone | Oil Prices Update - Business and Economy | NBC News Clone | Amazon Prime Sales - Business and Economy | NBC News Clone | Bitcoin Etf Approval - Business and Economy | NBC News Clone | Latest Vaccine Developments - Health and Medicine | NBC News Clone | Covid Variants Update - Health and Medicine | NBC News Clone | Boosters New Guidelines - Health and Medicine | NBC News Clone | Anxiety Depression Treatment - Health and Medicine | NBC News Clone | Longevity Research - Health and Medicine | NBC News Clone | Diet Trends 2025 - Health and Medicine | NBC News Clone | Workout Routines - Health and Medicine | NBC News Clone | Fda Approvals 2025 - Health and Medicine | NBC News Clone | Ukraine Russia Conflict Updates - World News | NBC News Clone | Israel Palestine War News - World News | NBC News Clone | China Taiwan Tensions - World News | NBC News Clone | Middle East Peace Talks - World News | NBC News Clone | European Union Politics - World News | NBC News Clone | Development News - World News | NBC News Clone | North Korea Missile Test - World News | NBC News Clone | Brazil Election - World News | NBC News Clone | Openai Chatgpt News - Technology and Innovation | NBC News Clone | Google Bard Ai - Technology and Innovation | NBC News Clone | Ai Regulation Laws - Technology and Innovation | NBC News Clone | Tiktok Ban Update - Technology and Innovation | NBC News Clone | Data Breaches 2025 - Technology and Innovation | NBC News Clone | Iphone 16 Release - Technology and Innovation | NBC News Clone | Nasa Mars Mission - Technology and Innovation | NBC News Clone | Web3 Developments - Technology and Innovation | NBC News Clone | 2024 Paris Games Highlights - Sports and Recreation | NBC News Clone | Super Bowl 2025 Preview - Sports and Recreation | NBC News Clone | Nba Playoffs 2025 - Sports and Recreation | NBC News Clone | Champions League Finals - Sports and Recreation | NBC News Clone | World Series 2025 - Sports and Recreation | NBC News Clone | Masters Tournament 2025 - Sports and Recreation | NBC News Clone | Extreme Weather Events - Weather and Climate | NBC News Clone | Hurricane Season 2025 - Weather and Climate | NBC News Clone | Global Warming Report - Weather and Climate | NBC News Clone | Weekly Weather Update - Weather and Climate | NBC News Clone | Earthquake Alerts - Weather and Climate | NBC News Clone | Solar Storm Warning - Weather and Climate | NBC News Clone | Hollywood Updates - Entertainment and Celebrity | NBC News Clone | Oscar Nominations 2025 - Entertainment and Celebrity | NBC News Clone | Grammy Awards 2025 - Entertainment and Celebrity | NBC News Clone | Netflix New Releases - Entertainment and Celebrity | NBC News Clone | Video Game Releases - Entertainment and Celebrity | NBC News Clone | Bestseller List - Entertainment and Celebrity | NBC News Clone | Government Transparency - Investigations and Analysis | NBC News Clone | Political Corruption - Investigations and Analysis | NBC News Clone | Big Tech Monopoly - Investigations and Analysis | NBC News Clone | Data Privacy Scandal - Investigations and Analysis | NBC News Clone | Community Stories - Local News and Communities | NBC News Clone | Nyc Mayor News - Local News and Communities | NBC News Clone | La Wildfires Update - Local News and Communities | NBC News Clone | Hurricane Preparedness - Local News and Communities | NBC News Clone